| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699028 | Clinical Oncology | 2014 | 5 Pages |
Abstract
The place of bevacizumab in the management of advanced non-small cell lung cancer (NSCLC) was reviewed. Particular reference has been made to the recent research on the systemic treatment of NSCLC indicating that treatment tailored to specifically identified morphology or genetic profile has recently changed practice. The result of this recent research means that bevacizumab has little, if any, place in the treatment of NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Snee,